Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTBP2 | P56545 | 1/20 | 0.47 |
| ▸ | KCNJ5 | P48544 | 2/20 | 0.47 |
| ▸ | KCNJ3 | P48549 | 2/20 | 0.47 |
| ▸ | KCNJ6 | P48051 | 1/20 | 0.47 |
| ▸ | PKM | P14618 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | SHBG | P04278 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | RIPK1 | Q13546 | 3/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | CNR2 | P34972 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8446184 | 0.85 | ALDH1A1 (0.50) | CTBP2KCNJ5KCNJ3KCNJ6PKM | |
| SCHEMBL13061948 | 0.81 | RIPK1 (0.60) | KCNJ5KCNJ3KCNJ6NPC1RAB9A | |
| SCHEMBL8676604 | 0.78 | CES1 (0.55) | CTBP2KCNJ5KCNJ3KCNJ6PKM | |
| SCHEMBL6960850 | 0.77 | CTBP2 (0.56) | CTBP2KCNJ5KCNJ3PKMNPC1 | |
| SCHEMBL9208767 | 0.76 | RAB9A (0.46) | CTBP2KCNJ5KCNJ3KCNJ6LMNA | |
| SCHEMBL7150897 | 0.76 | CTBP2 (0.51) | CTBP2KCNJ5KCNJ3KCNJ6PKM | |
| SCHEMBL1538109 | 0.76 | CES1 (0.57) | CTBP2NPC1RAB9AALDH1A1RIPK1 | |
| SCHEMBL265672 | 0.75 | CTBP2 (0.55) | CTBP2KCNJ5KCNJ3KCNJ6PKM | |
| SCHEMBL5529639 | 0.75 | RIPK1 (0.70) | LMNAPOLBNPC1RAB9AALDH1A1 | |
| SCHEMBL31365969 | 0.74 | CTBP2 (0.58) | CTBP2KCNJ5KCNJ3PKMPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100317621-A1 | BETA-LACTAMASE INHIBITORS | PROTEZ PHARMACEUTICALS, INC. | 2010-12-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100317621-A1 | BETA-LACTAMASE INHIBITORS | GANAB, BPGM, BLVRB | CTBP2 3407/4885KCNJ5 2625/4885KCNJ3 2839/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.